Quantcast

Latest Lymphocytic Leukemia Stories

2014-12-12 08:26:10

SUNNYVALE, Calif., Dec.

2014-12-08 20:20:41

IMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months SAN FRANCISCO and RARITAN, N.J.,

2014-12-08 20:20:32

Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc.

2014-12-08 20:20:25

Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif., Dec.

2014-12-07 20:21:07

- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia NORTH CHICAGO, Ill., Dec.

2014-12-06 16:21:17

- Note: This press release corresponds to abstract 31. SAN FRANCISCO, Dec. 6, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc.

2014-12-06 16:21:12

--CHOP-Led Pilot Study Engineers Patients' Own Immune Cells to Hunt Down Cancer Cells in Blood-- PHILADELPHIA, Dec.

2014-12-06 16:21:05

- Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions[1] EAST HANOVER, N.J., Dec.

2014-12-06 12:21:46

78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle THOUSAND OAKS, Calif., Dec.


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related